|
Phase I Trial of S-1153 in Patients With HIV Infection Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase I Trial of S-1153 in Patients With HIV Infection conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Trial of S-1153 in Patients With HIV Infection Clinical research trials and Phase I Trial of S-1153 in Patients With HIV Infection healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase I Trial of S-1153 in Patients With HIV Infection. Phase I Trial of S-1153 in Patients With HIV Infection Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase I Trial of S-1153 in Patients With HIV Infection clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase I Trial of S-1153 in Patients With HIV Infection condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Trial of S-1153 in Patients With HIV Infection  Phase I Trial of S-1153 in Patients With HIV Infection
Phase I Trial of S-1153 in Patients With HIV Infection
For Condition: HIV Infections
Status: Completed
Sponsor(s): Lexigen Pharmaceuticals ,
Synopsis: To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153 administration through evaluation of CD4 and viral load measurements.
Details: Two separate schedules of S-1153 are administered on this study: single dose (2 dose levels/cohorts) and repeated dose administration over 14 days (escalation through 4 dose levels/cohorts). All doses are determined by body weight. Single-dose study (Cohort 1): (4 patients) low-dose po, following a standardized morning meal. (4 patients) low-dose po, fasting. Single-dose study (Cohort 2), administered during the first 3 levels of the repeated dose study and prior to the initiation of the 4th repeated dose level: (4 patients): intermediate-dose po, following a standardized morning meal. (4 patients): intermediate-dose po, fasted. Following treatment with S-1153, all single-dose patients (Cohorts 1and 2) are observed for 21 days. Repeated dose (escalation) study: All doses are administered for 14 days. Three patients are entered at the starting dose of S-1153. In the absence of dose-limiting toxicity (DLT), subsequent 3-patient cohorts are entered at 3 escalating doses. The last patient at any given dose level must be observed for 21 days prior to entry of patient at the next dose. If 1 of the initial 3 patients experiences DLT at a given level, 3 additional patients will be added at that dose; if no additional toxicity occurs, escalation resumes. If 2 or more patients at a given dose exhibit DLT, the previous dose is declared the maximum tolerated dose (MTD) and 3 additional patients (6 total) are treated at that dose.
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: 1. Required for patients with CD4 cell count lower than 200: - PCP prophylaxis with aerosolized pentamidine, trimethoprim/sulfamethoxazole, mepron, or dapsone. - Allowed: - Continuation on an approved antiretroviral agent other than non-nucleoside reverse transcriptase inhibitors (e.g., Nevirapine) or other specifically excluded prior medications, if received without complications for at least 4 weeks prior to study entry. Patients must have: - Serologically documented HIV infection. - Single-dose patients: - CD4 cell count greater than 50 (no upper limit for single-dose cohorts). Repeated-dose patients: - CD4 count from 50 to 500 within 35 days prior to entrance on study. - No active opportunistic infection. Prior Medication: Allowed for entry onto multiple-dose study: - Single-dose portion of S-1153 study, provided all study visits and evaluations are completed, all eligibility criteria are met, and a minimum of 30 days has elapsed before Day 1 of the repeated-dose administration. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Active opportunistic infection. Concurrent Medication: Excluded: Concomitant use (within 5 half-lives prior to administration and for at least 24 hours following cessation of treatment with S-1153) of highly plasma-bound drugs with narrow therapeutic indices, including but not limited to coumadin and dilantin. Prior Medication: 1. Investigational new drugs. - Excluded within 30 days prior to study entry: - Chronic (greater than 7 days) use of drugs known to affect or be extensively metabolized by cytochromes P450, including but not limited to ketoconazole, fluconazole, itraconazole, isoniazid, rifampin, rifabutin, astemizole, terfenadine, or protease inhibitors. Prior Treatment: Excluded within 3 weeks prior to study entry: - Cytotoxic chemotherapy. - Interferon treatment. - Radiation therapy.
Total Enrollment: 40
Location and Contact Information:
Beth Israel Deaconess Med Ctr
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: 286A; 9616T0311,51,197
Study Start Date:
Record last reviewed: July 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002214
Other Hiv Infections Studies:
1. A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
2. A Comparison of 141W94 and Indinavir in HIV-Infected Patients
3. Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
4. A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment
5. Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Phase I Trial of S-1153 in Patients With HIV Infection
|
|
|
|
|
|
|
|
